Daily Cosmetic Research Analysis
Analyzed 3 papers and selected 3 impactful papers.
Summary
A randomized trial found collagen fillers deliver superior immediate and 3‑month aesthetic outcomes for nasolabial folds, while hyaluronic acid sustains better corrections at 6 months. An oncoplastic bilateral reduction mammoplasty series in breast cancer showed acceptable complication rates without delaying adjuvant therapy. Comparative degumming of Idesia polycarpa phospholipids maps processing effects relevant to cosmetic/dermal formulations.
Research Themes
- Injectable fillers for facial rejuvenation
- Oncoplastic breast surgery and cosmetic symmetry
- Processing chemistry of phospholipids for cosmetic applications
Selected Articles
1. A Prospective Study Comparing the Efficacy of Hyaluronic Acid and Collagen in the Treatment of Nasolabial Folds.
In a randomized trial (n=100), collagen and hyaluronic acid achieved similar nasolabial fold reductions initially and at 3 months, but hyaluronic acid maintained superior correction at 6 months. GAIS favored collagen for immediate and 3‑month outcomes, while hyaluronic acid showed better durability.
Impact: Provides head‑to‑head randomized evidence to guide filler choice based on trade‑offs between rapid improvement and longevity.
Clinical Implications: For patients prioritizing quick, downtime‑sparing improvement, collagen may be preferred; for those seeking longer durability, hyaluronic acid may be optimal. Counseling should align product selection with patient goals.
Key Findings
- Randomized allocation of 100 patients showed no baseline imbalances between groups.
- Collagen and hyaluronic acid provided similar NLF reductions initially and at 3 months.
- At 6 months, hyaluronic acid maintained significantly greater NLF improvements than collagen.
- GAIS favored collagen immediately and at 3 months, while hyaluronic acid had better aesthetic maintenance at 6 months.
Methodological Strengths
- Prospective randomized controlled design with trial registration (ChiCTR2500106800)
- Standardized photographic assessment with GAIS at predefined timepoints
Limitations
- Blinding and assessor masking were not specified, risking measurement bias
- Safety outcomes and adverse events were not detailed in the abstract
- Tailored dosing may introduce variability across participants
Future Directions: Conduct blinded, assessor‑masked RCTs with standardized dosing and comprehensive safety monitoring over 12+ months, including objective 3D imaging and patient‑reported outcomes.
BACKGROUND: Hyaluronic acid (HA) is established as the gold standard for nasolabial folds (NLFs) correction. However, its use is frequently associated with transient edema and potential migration. These limitations have spurred investigation into collagen-based fillers as viable alternatives characterized by comparable efficacy and a favorable safety profile. OBJECTIVE: This prospective randomized controlled trial aimed to evaluate the comparative effectiveness of HA and collagen fillers in NLFs augmentation. METHODS: Between January 2022 and December 2023, 100 patients with moderate to severe NLFs (Wrinkle Severity Rating Scale Grades 2-4) were enrolled and randomly allocated to receive either collagen (n = 50) or HA (n = 50) injections. Treatment protocols employed tailored injection doses according to baseline NLFs severity and indentation depth. Global Aesthetic Improvement Scale (GAIS) evaluation of standardized photographs was performed to assess outcomes at baseline, 3 months, and 6 months. RESULTS: Baseline characteristics showed no intergroup disparities. Both materials produced similar improvements in NLFs reduction initially and at 3 months. At 6 months, HA maintained significantly greater improvements in NLF dimensions compared with collagen. GAIS scores indicated superior immediate and 3-month aesthetic outcomes with collagen, while HA showed better aesthetic maintenance at 6 months. CONCLUSION: This study demonstrated comparable short-term efficacy between collagen and HA for NLFs correction. These findings suggest collagen may be a practical alternative for patients seeking rapid correction with minimal downtime, while HA remains superior for long-term correction. Treatment selection should therefore be individualized based on patient preference for immediate improvement or longevity. TRIAL REGISTRATION: Clinical Trial Registry: ChiCTR2500106800.
2. Comparative analysis of degumming effects on the structural profiles and physicochemical properties of Idesia polycarpa phospholipids.
The study systematically compares six degumming processes for Idesia polycarpa phospholipids, focusing on how processing alters structural profiles and physicochemical properties. Findings inform optimization of phospholipid ingredients relevant to food and cosmetic formulations.
Impact: Provides comparative processing insights that can tune phospholipid properties for formulation science, relevant to dermal/cosmetic delivery systems.
Clinical Implications: While preclinical, refined phospholipid processing can influence stability, delivery, and tolerability of topical/cosmetic formulations.
Key Findings
- Idesia polycarpa oil by-products contain abundant phospholipids, warranting compositional and functional analysis.
- Six degumming methods, including hydration and acid degumming and phospholipase A-mediated approaches, were comparatively evaluated.
- Structural profiles and physicochemical properties of phospholipids were characterized across processing methods.
Methodological Strengths
- Head-to-head comparison of multiple industrially relevant degumming processes
- Focus on both structural profiling and physicochemical property characterization
Limitations
- Abstract truncation limits visibility into quantitative outcomes and statistical analyses
- Clinical translation is indirect as work is preclinical/material-science focused
Future Directions: Quantify how each degumming route alters lipid subclasses and functionality, and validate formulation performance (stability, penetration) in dermal models.
Idesia polycarpa (I. polycarpa) oil by-products are rich in phospholipids (PLs), yet research on their composition and functionality remains limited. This study compared six degumming methods-hydration degumming (HD), acid degumming (AD), phospholipase A
3. Can Bilateral Reduction Mammoplasty Be Safely Performed in Breast Cancer Patients With Macromastia?
In 30 early‑stage breast cancer patients undergoing oncoplastic BRM with contralateral symmetrization, major complications occurred only on the malignant side (10%), with three reoperations; no reoperations were needed on the reduction‑only side. No adjuvant therapy delays occurred, and BREAST‑Q scores indicated high satisfaction.
Impact: Offers pragmatic safety and satisfaction data supporting BRM as an oncoplastic option to enable radiotherapy planning and symmetry in macromastia with breast cancer.
Clinical Implications: BRM with contralateral symmetrization can be considered for macromastia in early breast cancer without delaying adjuvant therapy, with careful monitoring of the malignant side for complications.
Key Findings
- Among 30 patients (median age 52), major complications occurred only on the malignant side (10%).
- Three patients required reoperation on the malignant breast; no reoperations were needed on the reduction-only side.
- Minor complications were managed outpatient, and no adjuvant therapy was delayed.
- Median BREAST-Q scores were high: psychosocial 79, satisfaction with breasts 82, medical team 100, information 91.
Methodological Strengths
- Prospective collection across a defined period with standardized complication classification
- Use of BREAST‑Q to quantify patient-reported satisfaction
Limitations
- Single-center, small sample case series without a control group
- Short-term follow-up; long-term oncologic and cosmetic durability not assessed
Future Directions: Multicenter prospective cohorts or pragmatic trials comparing BRM versus standard breast-conserving surgery with long-term oncologic, radiotherapy, and patient-reported outcomes.
BackgroundIn early-stage breast cancer patients with macromastia, radiotherapy following standard breast-conserving surgery may pose planning challenges due to large breast volume. Bilateral reduction mammoplasty (BRM) facilitates wider resections while improving radiotherapy planning and enhancing cosmetic symmetry.MethodsWe evaluated 30 patients undergoing BRM at the Surgical Oncology Clinic of Ankara Etlik City Hospital between October 2022 and May 2025. All patients received oncoplastic tumor resection on the malignant breast and contralateral reduction mammoplasty for symmetrization. We classified early postoperative complications as major or minor and examined outcomes in both malignant and reduction-only breast surgeries. We assessed patient satisfaction using the BREAST-Q questionnaire.ResultsPatients' median age was 52 years. Major complications were identified exclusively on the malignant side (10%). In three patients, reoperation and revision were performed due to major complications of the malignant breast, whereas no reoperation was required on the breast that underwent reduction alone. Minor complications were managed in the outpatient clinic. There was no delay in adjuvant treatment due to complications in any patient. Median BREAST-Q scores were as follows: 79 (range: 48-100) for psychosocial well-being, 82 (range: 45-100) for satisfaction with breasts, 100 (range: 61-100) for satisfaction with the medical team, and 91 (range: 62-100) for satisfaction with information.ConclusionBilateral reduction mammoplasty appears to be an oncologically safe and surgically feasible alternative for breast cancer patients with macromastia. The observed complication rates were within acceptable limits, and contralateral symmetrization did not result in any additional surgical burden for the patient.